Recent Advances in the Treatment
and Management of NASH

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from June 1, 2020 to June 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Intercept Pharmaceuticals

Nonalcoholic fatty liver disease (NAFLD) is a progressive spectrum of liver disorders that includes among its more severe forms nonalcoholic steatohepatitis (NASH). NASH is one of the most common causes of chronic liver disease worldwide, affecting an estimated 25% of the world's population. The disease can be characterized as inflammation of the liver and the damage caused by a buildup of fat in the liver and may worsen, causing scarring of the liver which can lead to cirrhosis. Closely associated with rising rates of obesity and metabolic syndrome, the prevalence of these conditions continues to increase creating a clinical and economic burden. NASH can lead to significant morbidity and mortality, including liver fibrosis and cirrhosis. NASH remains underdiagnosed and undertreated as patients may have no symptoms at all which makes it hard to diagnosis. As NASH continues to progress and the liver damage gets worse, patients may experience fatigue, weight loss, overall weakness and an ache in the upper right part of the belly.

Fatty liver disease and advanced forms of fibrosis have limited treatment options. The first line of treatment at this time is usually weight loss through a combination of a healthy diet and exercise. For those who have cirrhosis due to nonalcoholic steatohepatitis, liver transplantation may be an option. Outcomes of liver transplant in this population group are generally very good. NASH, described as the hepatic manifestation of metabolic syndrome, remains challenging to diagnose and treat, but significant advances have been made in the recent years. There are several agents that are on the horizon and still more that are in clinical trials that look promising to help treat this growing disease.

Upon completion of this activity, participants will be able to:

  • Discuss the pathogenesis and the pathophysiologic mechanisms for NAFLD and NASH

  • Assess the current guidelines and recommendations for appropriate diagnostic and treatment strategies of NAFLD and NASH in order to optimize proper management

  • Identify current assessment and diagnostic tools for NASH and their value in predicting patient outcomes

  • Analyze the efficacy and safety profiles of emerging treatments for NASH to achieve individualized treatment goals

  • Explore the challenges and opportunities in NASH disease management, including patient adherence, quality of life and total cost of care


Faculty: Romina Lomonaco, MD
Assistant Professor of Medicine
Division of Endocrinology
Diabetes and Metabolism
The University of Florida


Dr. Lomonaco has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Intercept Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue